Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab-rezetecan + pertuzumab + iparomlimab + tuvonralimab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy regimen is an investigational treatment being evaluated for the first-line management of HER2-expressing locally advanced or metastatic biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder carcinoma. The regimen integrates four distinct therapeutic agents: **trastuzumab-rezetecan** (SHR-A1811), a HER2-directed antibody-drug conjugate (ADC) featuring a topoisomerase I inhibitor payload (rezetecan); **pertuzumab**, a monoclonal antibody that inhibits HER2 dimerization; and **QL1706** (Qibeian), a bifunctional 'MabPair' product consisting of a fixed-ratio mixture of **iparomlimab** (an anti-PD-1 IgG4 antibody) and **tuvonralimab** (an anti-CTLA-4 IgG1 antibody). By combining dual HER2 blockade (via the ADC and pertuzumab) with dual immune checkpoint inhibition (PD-1 and CTLA-4), the regimen aims to maximize tumor cell killing through direct cytotoxicity and enhanced anti-tumor immune responses. It is currently under investigation in a Phase II clinical trial (NCT07129018) sponsored by Union Hospital, Tongji Medical College.
- Brand names
- Qibeian
- Other names
- trastuzumab-rezetecan + pertuzumab + iparomlimab + tuvonralimab-Union Hospital, Tongji Medical College, Huazhong University of Science and Technology-biliary tract cancerSHR-A1811 + pertuzumab + iparomlimab/tuvonralimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on trastuzumab-rezetecan + pertuzumab + iparomlimab + tuvonralimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab-rezetecan + pertuzumab + iparomlimab + tuvonralimab.